-
Scipher Medicine Increases Patient Access for PrismRA® by Expanding Intended Use in Autoimmune Patients -
Scipher Medicine Introduces Breakthrough Capability to Accelerate Drug Discovery -
Scipher Medicine Translates Complex Biology to Predict Better Outcomes -
Scipher Medicine Announces PrismRA® Met Primary and Secondary Endpoints in Prospective Observational Study Predicting Inadequate Response to World’s Largest-Selling Drug Class, TNFi -
Scipher Medicine Presents New Data at the European League Against Rheumatism (EULAR) 2021 Further Validating PrismRA® Test -
Scipher Medicine and Leading Medical Researchers in Network and Data Science Compress Time to Identify Covid-19 Treatments from Years to Months -
Scipher Applies SpectraTM Platform to Discover Drugs Targeting Autoimmune Patients Refractory to Existing Therapies -
A Conversation with Scipher Medicine Chief Technology Officer Slava Akmaev -
Scipher Medicine Announces $82 Million Financing -
Addressing wasted healthcare dollars and ineffective prescriptions -
Reduce Wasted Spend While Significantly Improving Clinical Outcomes -
Understanding protein interaction to optimize drug discovery -
WellDyne Partners with Scipher Medicine to Improve Patient Outcomes and Lower Costs for Rheumatoid Arthritis Care -
Scipher Medicine Brings Precision Medicine Platform to Patient-Centered MIT Initiative -
New Study Demonstrates Clinical Utility of PrismRA Test in Guiding Therapy Selection for Rheumatoid Arthritis Patients